Stock of the day: CSL Limited
CSL emerges as a standout performer, reporting a 20% profit increase driven by its blood plasma division. Discover how CSL’s strategic acquisitions and robust growth trajectory make it a compelling choice for investors.
[AI generated]
This video was created on 13 August for IG audiences by ausbiz.
Stock of the day: CSL Limited (ASX: CSL)
CSL outperforms market expectations
In today’s financial spotlight, CSL emerges as a standout performer despite broader market concerns. The global healthcare giant reported a 20% increase in full-year profit, driven by robust growth in its blood plasma division. CSL's profit surged to $2.64 billion, with the company projecting further earnings growth of 10-13% for the 2025 financial year.
Shareholder returns and market reaction
Investors are set to receive a substantial final dividend of $0.45 per share, pushing the total annual dividend to $2.64 - a 12% increase. The market responded positively to these results, with CSL’s stock price climbing by 4%. This rebound is notable as CSL’s share price had previously dipped to $230 over the last year but has since recovered to around $300.
Strategic acquisitions and outlook
Despite recent challenges, including high costs and the integration of a significant Swiss acquisition, CSL anticipates continued margin improvements. The company's strategic expansion into the containerised freight market and its existing robust infrastructure in Queensland and New South Wales underscore its growth trajectory.
CSL’s resilience and strategic acquisitions underscore its capability to sustain growth, making it a compelling choice for investors looking for stability and growth in the healthcare sector.
The information on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG Bank S.A. accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer.
Live prices on most popular markets
- Forex
- Shares
- Indices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
